MR contrast agents, the old and the new.

Magnetic resonance (MR) contrast agents are increasingly being used to help detect and characterize various neoplastic, inflammatory and functional abnormalities. The extracellular, non-specific contrast agents gadolinium chelates are by far the most widely used. Over the past few years a number of MR organ specific contrast agents have been introduced. MRI contrast agents are generally safe and well tolerated. The present review summarizes the properties, main characteristics and imaging applications of commercially available compounds as well as safety of these agents in normal and high-risk patients.

[1]  P. Wedeking,et al.  Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.

[2]  R. Semelka,et al.  Contrast agents for MR imaging of the liver. , 2005, Radiologic clinics of North America.

[3]  F. Lazeyras,et al.  Specificity of SPIO particles for characterization of liver hemangiomas using MRI , 2003, Abdominal Imaging.

[4]  M. Bellin,et al.  Currently used non-specific extracellular MR contrast media , 2003, European Radiology.

[5]  B. Hamm,et al.  Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: results of multicenter studies in Europe and the USA. , 1999, Journal of computer assisted tomography.

[6]  F. Shellock,et al.  Safety of magnetic resonance imaging contrast agents , 1999, Journal of magnetic resonance imaging : JMRI.

[7]  Henrik S. Thomsen,et al.  The use of iodinated and gadolinium contrast media during pregnancy and lactation , 2005, European Radiology.

[8]  K. Yoshikawa,et al.  Safety of ProHance in special populations , 1997, European Radiology.

[9]  R. Vré,et al.  Invited review: biophysical properties and clinical applications of magnetic resonance imaging contrast agents. , 1995, The British journal of radiology.

[10]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  M. Tweedle,et al.  The ProHance story: the making of a novel MRI contrast agent , 1997, European Radiology.

[12]  J. Hagan,et al.  Comparative chemical structure and pharmacokinetics of MRI contrast agents. , 1988 .

[13]  L. Martí-Bonmatí,et al.  Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis , 2003, European Radiology.

[14]  E. Rummeny,et al.  MnDPDP for MR imaging of the liver , 1997, Acta radiologica.

[15]  M. Schreiber.  The Shape of Things To Come , 1988 .

[16]  D. Khayat,et al.  Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. , 1994, Radiology.

[17]  J. Brunberg,et al.  Adverse reactions to gadolinium contrast media: a review of 36 cases. , 1996, AJR. American journal of roentgenology.

[18]  C. Claussen,et al.  MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties. , 1997, Radiology.

[19]  V. Lorusso,et al.  Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. , 1999, Academic radiology.

[20]  R Weissleder,et al.  Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. , 1988, Radiology.

[21]  A. Spinazzi,et al.  Interim results of phase II clinical testing of gadobenate dimeglumine. , 1994, Investigative radiology.

[22]  C. Chang,et al.  Magnetic resonance imaging contrast agents. Design and physicochemical properties of gadodiamide. , 1993, Investigative radiology.

[23]  P. Hals,et al.  Biodistribution and toxicity of MR imaging contrast media , 1993, Journal of magnetic resonance imaging : JMRI.

[24]  L. Vlahos,et al.  Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A) , 2001, Journal of magnetic resonance imaging : JMRI.

[25]  M. Kirchin,et al.  Safety assessment of gadobenate dimeglumine (MultiHance®): Extended clinical experience from phase I studies to post‐marketing surveillance , 2001, Journal of magnetic resonance imaging : JMRI.

[26]  T. R. Lucas,et al.  Safety of gadoteridol injection: U.S. clinical trial experience , 1995, Journal of magnetic resonance imaging : JMRI.

[27]  H. Thomsen,et al.  Oral manganese for liver and bile imaging. , 2005, Academic radiology.

[28]  V. Runge,et al.  Safety of approved MR contrast media for intravenous injection , 2000, Journal of magnetic resonance imaging : JMRI.

[29]  T. Southon,et al.  Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration , 1997, Acta radiologica.

[30]  W F Bennett,et al.  Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging , 2000, Journal of magnetic resonance imaging : JMRI.

[31]  M. Bellin,et al.  Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure. , 1992, Magnetic resonance imaging.

[32]  D. Bluemke,et al.  Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol. , 2003, Radiology.

[33]  A. Spinazzi,et al.  Gadobenate dimeglumine (Gd-BOPTA). An overview. , 1998, Investigative radiology.

[34]  P. Cluzel,et al.  Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences , 1999, European Radiology.

[35]  J. Debatin,et al.  Gadopentetate dimeglumine excretion into human breast milk during lactation. , 2000, Radiology.

[36]  S. McGill,et al.  MnDPDP for MR imaging of the liver , 1997, Acta radiologica.

[37]  H. Thomsen,et al.  Safety of MR liver specific contrast media , 2005, European Radiology.

[38]  S E Seltzer,et al.  Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. , 1995, Radiology.

[39]  G. Marchal,et al.  Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study. , 2000, Radiology.

[40]  P. Robinson,et al.  Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. , 2004, Radiology.

[41]  M. Tweedle,et al.  Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. , 1992, Investigative radiology.